Dyadic International, Inc. — Third Quarter 2026 Earnings Summary

Dyadic International, Inc. reported a net loss of $1,357,041 for the third quarter ended September 30, 2026, driven by a 61.4% decline in total revenue to $449,101. The company achieved a significant milestone by recording its first direct commercial product sales of recombinant transferrin and DNase I, while also expanding distribution through Integrated Biotherapeutics. Strategic partnerships advanced with Proliant promoting AlbuFree DX and Inzymes commercializing a second chymosin product, alongside continued progress on the C1 biopharmaceutical platform for vaccine and antibody development. As of September 30, 2026, the company held $6,046,083 in cash and equivalents, reflecting a decrease from the previous year-end balance.